At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
03692 HANSOH PHARMA
Not Yet Opened 05-21 16:08:15
34.100
+0.500
+1.49%
High34.340
Low33.440
Vol8.88M
Open33.800
D1 Closing33.600
Amplitude2.68%
Mkt Cap206.78B
Tradable Cap206.78B
Total Shares6.06B
T/O301.32M
T/O Rate0.15%
Tradable Shares6.06B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
HANSOH PHARMA's Fourth-Generation EGFR Inhibitor HS-10504 Granted Breakthrough Therapy Designation for Lung Cancer
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.